Nakatsu, Japan

Takanori Oe

This inventor holds 14 USPTO granted patents. Top assignee: Yoshitomi Pharmaceutical Industries, Ltd.. Active years: 1976-1991.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Takanori Oe. Retrieved from https://idiyas.com/inventor/takanori-oe

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 3.5

ph-index = 6

Forward Citations = 87(Granted Patents)


Location History:

  • Oita, JA (1976)
  • Nakatsu, JA (1976 - 1978)
  • Oita, JP (1978 - 1991)
  • Nakatsu, JP (1983 - 1991)

Company Filing History:


Years Active: 1976-1991

Loading Chart...
14 patents (USPTO):Explore Patents

Title: Takanori Oe: Innovator in Pharmaceutical Compounds

Introduction

Takanori Oe is a prominent inventor based in Nakatsu, Japan. He has made significant contributions to the field of pharmaceuticals, holding a total of 14 patents. His work focuses on innovative compounds that have potential therapeutic applications.

Latest Patents

Among his latest patents are the development of fused pyrazole compounds and their pharmaceutical uses. Additionally, he has worked on pyridine compounds, including a novel pyridine compound that exhibits inhibitory activity against prolylendopeptidase. These compounds are crucial for advancing pharmaceutical treatments.

Career Highlights

Takanori Oe is associated with Yoshitomi Pharmaceutical Industries, Ltd., where he continues to push the boundaries of pharmaceutical research. His expertise in compound development has positioned him as a key player in the industry.

Collaborations

Throughout his career, Takanori has collaborated with notable colleagues, including Mineo Tsuruda and Kazuyuki Kawasaki. These partnerships have fostered innovation and contributed to the success of their projects.

Conclusion

Takanori Oe's work in pharmaceutical innovations exemplifies the impact of dedicated inventors in advancing medical science. His contributions continue to shape the future of pharmaceutical development.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…